CA-INVIVOSCRIBE
Today Invivoscribe, a global leader in precision diagnostics, announced the launch of a new 12-color multiparametric flow cytometry service in Shanghai, China, the newest reference laboratory in their international LabPMM network. Flow cytometry has long been the standard of care for many blood cancers including acute myeloid leukemia (AML), but to achieve minimal residual disease (MRD) level sensitivity with limited specimen, powerful 12-color multiparametric flow cytometry (MFC) is needed. By providing the combination of 12-color flow cytometry and next-generation sequencing (NGS) MRD capabilities in the US, in Europe, and also in China, Invivoscribe now offers a comprehensive international solution for our pharma partners.
Invivoscribe’s globally standardized network of LabPMM reference laboratories offer best in class NGS assays, gene panels, and bioinformatics software, to complement our new MFC panels. The addition of 12-color MFC panels to our existing NGS capabilities, eliminates the need to split primary subject specimens and have them tested in multiple labs. It also allows the same pull of bone marrow to be tested using several complementary technologies, so pharma partners can obtain and compare results leveraging limited samples using targeted assays and technologies for drug development and clinical studies. By offering both MFC and NGS testing in our international laboratories, Invivoscribe can accelerate clinical trials and streamline drug approvals.
“We are very fortunate to have exceptional scientists leading our Flow Cytometry Services,” says Tony Lialin, Chief Commercial Officer at Invivoscribe. “Our hematopathologists are domain experts that have an intimate understanding of hematologic malignancies, the markers, and the instrumentation gained from their decades of experience. When we were developing our flow assays we had three goals: (1) to provide partners with one-stop international screening and MRD testing, (2) to leverage our infrastructure to quickly develop panels to meet novel partner needs, and (3) to provide standardized CAP/CLIA testing in all of our ISO 15189 accredited global laboratories. We are excited about our unique offering in Asia and we are well-positioned to help our pharma partners accelerate clinical studies and approval of their novel therapies worldwide.”
Leveraging an international network of our wholly-owned clinical reference laboratories, Invivoscribe can rapidly design and validate custom panels, track MRD for a range of oncologic diseases, including solid tumors, and develop and commercialize companion diagnostic assays for pharma partners.
About Invivoscribe
Invivoscribe® has been Improving Lives with Precision Diagnostics® for more than twenty-five years, advancing the field of precision medicine by developing and selling standardized reagents, tests, and bioinformatics tools to more than 700 customers in 160 countries. Invivoscribe also has a significant impact on global health working with pharmaceutical companies to accelerate approvals of new drugs and treatments by supporting international clinical trials, developing, commercializing companion diagnostics, and providing expertise in both regulatory and laboratory services. With its proven ability to provide global access to distributable reagents, kits, and controls, as well as clinical trial services through our international clinical lab subsidiaries (LabPMM® ), Invivoscribe has demonstrated it is an ideal partner. For additional information please contact Invivoscribe at businessdevelopment@invivoscribe.com or visit us at www.invivoscribe.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005914/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech and Equinor Expand Digital Collaboration2.7.2025 13:08:00 CEST | Press release
HCLTech, a global technology leader, and Equinor, Europe's largest energy supplier and a pioneer in renewables and low-carbon solutions, have expanded their IT collaboration to support the next phase of Equinor’s digital transformation. This expanded relationship will cover Equinor’s IT landscape across several key strategic areas. HCLTech will support Equinor as it accelerates its digital transformation by: Accelerating its cloud migration and standardizing services across operations Enhancing its cyber resilience and network performance Improving workplace experience through automation Enabling advanced user experiences with technologies like augmented reality (AR) "We’re pleased to continue our long-standing collaboration with Equinor," said Sandeep Kumar Saxena, Executive Vice President, HCLTech. "This collaboration reflects our shared commitment to innovation and sustainability.” Over the past decade, HCLTech has been a trusted advisor to Equinor, supporting the company’s global e
Wizz Air Tops Major Airline Emissions Rankings2.7.2025 11:00:00 CEST | Press release
Cirium, the aviation analytics company, creates a new transparent standard and ranking for airline CO2 emissions, identifying the best performing airlines in specific categories Wizz Air is the world's most emissions-efficient airline in new rankings released today by Cirium, the aviation analytics firm. The Cirium Flight Emissions Review ranks the top 20 airlines globally, through a consistent benchmark for flight emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702342529/en/ The top 20 Major airlines globally, ranked by lowest CO2/ASK Wizz Air, the Hungary-based ultra-low-cost airline emits an industry low of 53.9 grams of CO₂ per Available Seat Kilometer (ASK)*, followed by Frontier Airlines (54.4 grams) and Pegasus (57.1 grams) according to the report. The rankings provide the aviation industry with verified comparable data on an equal playing field as the sector advances toward Net Zero by 2050 commitments.
L&T Technology Services Chosen by TRATON GROUP as Strategic Engineering Partner in Global R&D Transformation2.7.2025 10:59:00 CEST | Press release
Multi-year collaboration in LTTS’ Mobility segment to drive platform synergies, electrification, and innovation for TRATON GROUP L&T Technology Services (BSE: 540115, NSE: LTTS), today announced that it has been chosen by the TRATON GROUP, one of the world’s leading manufacturers of commercial vehicles, as a strategic engineering partner. This collaboration in LTTS’ Mobility segment will support TRATON’s roadmap to build a unified, future-ready product-development platform that delivers scale, speed, and sustainable mobility solutions worldwide. TRATON is reshaping its global R&D ecosystem to unlock cross-brand synergies while expanding the share of battery-electric vehicles in line with its 2029 profitability and sustainability targets. LTTS’ selection will see the company provide engineering support, from mechanical and software engineering to digital systems integration - across key development hubs in Sweden, Germany, the United States, Poland, and India. The collaboration position
Nexo Becomes First-Ever Digital Wealth Platform of the DP World Tour, Launches Nexo Championship2.7.2025 10:30:00 CEST | Press release
Named Official Digital Wealth Platform of the DP World Tour through 2027 Nexo becomes Title Partner of the Nexo Championship, which takes place at Trump International Golf Links in August 2025 Nexo, the premier digital assets wealth platform, has signed a three-year landmark partnership with the DP World Tour, becoming an Official Marketing Partner and the Tour’s Official Digital Wealth Platform through 2027. This agreement marks the first-ever multi-year partnership between a digital assets company and a major global golf tour — a historic convergence of crypto and golf — reflecting both organizations’ shared commitment to performance, innovation, and a global outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702770847/en/ Nexo becomes the first-ever Official Digital Wealth Platform of the DP World Tour. Nexo has also become the Title Partner of the newly renamed Nexo Championship — previously the Scottish Champion
Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta2.7.2025 10:00:00 CEST | Press release
Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing for Rekovelle® (follitropin delta); alongside its existing unique algorithm-based dosing Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) gonadotrophin-releasing hormone (GnRH) antagonist protocol cycles. This is the key finding of a trial presented today at the European Society of Human Reproduction and Embryology (ESHRE) Congress in Paris and published in Human Reproduction. These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications.1,2 The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 wome
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom